Half-year report on INNATE PHARMA’S liquidity contract with NATIXIS SECURITIES

Under the liquidity contract entrusted by Innate Pharma to Natixis Securities, the following assets appeared on the liquidity account as at December 31, 2009:

• 69,741 shares of Innate Pharma, and
• 121,955.05 euros in cash.

For information, the following assets appeared on the liquidity account at its start:

• 300,000 euros in cash